
PMC:7091888 / 16498-16695
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
785 | 80-85 | Gene | denotes | hACE2 | Gene:59272 |
795 | 13-23 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
796 | 46-56 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
814 | 97-101 | CellLine | denotes | 293T | CVCL:0063 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T127 | 28-35 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T128 | 102-107 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T259 | 13-21 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T260 | 13-17 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T261 | 46-54 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T262 | 46-50 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T314 | 97-101 | http://purl.obolibrary.org/obo/CLO_0050894 | denotes | 293T |
T315 | 97-101 | http://purl.obolibrary.org/obo/CLO_0051650 | denotes | 293T |
T316 | 97-101 | http://purl.obolibrary.org/obo/CLO_0052052 | denotes | 293T |
T317 | 102-107 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T318 | 111-112 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T78 | 28-35 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T98 | 0-197 | Sentence | denotes | As expected, SARS-CoV-2 RBD protein inhibited SARS-CoV-2 pseudovirus entry into hACE2-expressing 293T cells in a dose-dependent manner with 50% inhibition concentration (IC50) as low as 1.35 µg/ml. |